Tag Archive for: COVID-19

Destiny Pharma and SporeGen® announce update from research collaboration under Innovate UK grant award to develop a biotherapeutic treatment (SPOR-COV®) for COVID-19 and Influenza

/in

Positive results from testing SPOR-COV in several COVID-19 and influenza research models support potential as prophylactic nasal spray Toxicology studies support safety profile Manufacturing process established Manufacturing and regional licensing agreement signed with HURO Biotech JSC for Vietnam Phase 1 clinical studies completed successfully in Vietnam by HURO Retail product based on SPOR COV technology […]

Read more

Pandemic Antiviral Discovery (PAD) makes first investments to support the development of new antiviral medicines for future pandemics

/in

Fourteen research projects will focus on antiviral research and drug development for henipaviruses, a subgroup of viruses with pandemic potential. Today, the partners in Pandemic Antiviral Discovery (PAD) initiative announced grants totalling more than USD 26 million for 14 research projects aimed at facilitating early-stage development of drugs to treat henipavirus infection and disease in […]

Read more

eTheRNA: New agreement paves way for development of first African-owned COVID-19 vaccine

/in

A year after the establishment of the mRNA Vaccine Technology Transfer Hub, Afrigen and Univercells enter a new agreement to develop the first African-own COVID-19 vaccine  CAPE TOWN (SOUTH AFRICA) & BRUSSELS (BELGIUM), JUNE 21, 2022 – One year since the establishment of the mRNA Vaccine Technology Transfer Hub, a collaboration between two of the […]

Read more

Covid-19: The Industry Response – How Are we Doing?

/in

Chair: Clive Cookson, Science Editor, Financial Times Sean Marett, Chief Business and Chief Commercial Officer, BioNTech Professor James Logan, Head of Department of Disease Control, London School of Hygiene and Tropical Medicine Kate Bingham, Chair of UK Vaccine Taskforce & Managing Partner of SV Health Investors Rajeev Venkayya, MD, President Global Vaccine Business Unit, Takeda […]

Read more